BackKala Bio Overview

Kala Bio Current Cash

Latest current cash for KALA: $230K.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$229000.00
↓ 99.28% YoYΔ $-31.71M vs prior year quarter

Peer trimmed avg / median

Loading

Kala Bio Current Cash History

Loading

Kala Bio vs. peers: Current Cash Comparison

Loading

Kala Bio Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Kala Bio (KALA) FAQ

As of the most recent data (June 2026), KALA shows a current cash of $230K. That compares with $32M in the prior-year period — down 99.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, KALA's current cash is now $230K (was $32M) — a 99.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Kala Bio is outperforming or lagging.

Tracking KALA's current cash over time shows whether Kala Bio is scaling, shrinking, or reshaping that part of the business. The current reading is $230K That compares with $32M in the prior-year period — down 99.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Kala Bio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $230K) with ownership activity and broader fundamentals.

Kala Bio's current cash is $230K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.